GlassScriptPhysician profile
Young J Ko
NPI 1639277130
$8,744.82
in general payments reported to CMS, 2019-2025
14 companies · $7,873 in 2025
The $7,873 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $395 · 2020: $110 · 2021: $128 · 2022: $34.09 · 2023: $191 · 2024: $14.04 · 2025: $7,873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $7,057 · Travel and Lodging: $813 · Food and Beverage: $208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $7,057.48 |
| Travel and Lodging | $812.98 |
| Food and Beverage | $208.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $7,945.12 | 2021-2025 | |
| Glaxosmithkline, LLC. | $173.20 | 2019 | |
| Penumbra, INC. | $133.83 | 2023 | Indigo System |
| Genentech USA, INC. | $110.53 | 2019-2020 | |
| Insmed, INC. | $83.44 | 2020-2025 | Arikayce, Brinsupri |
| Sunovion Pharmaceuticals INC. | $64.15 | 2019 | |
| Merck Sharp & Dohme LLC | $60.18 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $57.48 | 2023 | |
| Allergan, INC. | $39.73 | 2019-2020 | |
| Csl Behring | $35.80 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.04 | 2024 | Ofev |
| Gilead Sciences, INC. | $13.68 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $11.14 | 2021 | |
| United Therapeutics Corporation | $2.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Young Ko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.